Intravesical Gene Therapy

Vikram M Narayan1, Colin P N Dinney2

  • 1University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA. Electronic address: https://twitter.com/VikramNarayan.

Insights

Non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG) treatment presents challenges. Intravesical gene therapy offers a promising alternative for patients unable or unwilling to undergo radical cystectomy.

Area of Science:

  • Oncology
  • Urology
  • Gene Therapy

Background:

  • Non-muscle-invasive bladder cancer (NMIBC) is difficult to treat, especially when unresponsive to bacillus Calmette-Guerin (BCG) therapy.
  • Radical cystectomy with pelvic lymphadenectomy is the standard treatment for BCG-unresponsive NMIBC.
  • There is a significant need for alternative treatments for patients who cannot or will not undergo surgery.

Purpose of the Study:

  • To explore intravesical gene therapy as a potential treatment for BCG-unresponsive NMIBC.
  • To highlight the unmet need for salvage options in NMIBC management.
  • To discuss the emerging role of gene therapy in bladder cancer treatment.

Main Methods:

  • Review of current treatment landscape for NMIBC.
  • Exploration of intravesical gene therapy as a novel therapeutic approach.
  • Discussion of early data and ongoing research in gene therapy for bladder cancer.

Main Results:

  • Intravesical gene therapy shows promise as an alternative to radical cystectomy.
  • Early data suggests potential efficacy in treating BCG-unresponsive NMIBC.
  • Further research is needed to optimize gene therapy mechanisms and outcomes.

Conclusions:

  • Intravesical gene therapy represents a potential breakthrough for managing challenging NMIBC cases.
  • This approach addresses the limitations of current salvage options.
  • Understanding the mechanisms of action is crucial for advancing gene therapy in bladder cancer treatment.